279 related articles for article (PubMed ID: 23827191)
1. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.
Loessner D; Rizzi SC; Stok KS; Fuehrmann T; Hollier B; Magdolen V; Hutmacher DW; Clements JA
Biomaterials; 2013 Oct; 34(30):7389-400. PubMed ID: 23827191
[TBL] [Abstract][Full Text] [Related]
2. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
[TBL] [Abstract][Full Text] [Related]
4. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells.
Loessner D; Stok KS; Lutolf MP; Hutmacher DW; Clements JA; Rizzi SC
Biomaterials; 2010 Nov; 31(32):8494-506. PubMed ID: 20709389
[TBL] [Abstract][Full Text] [Related]
5. Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach.
Loessner D; Flegg JA; Byrne HM; Clements JA; Hutmacher DW
Integr Biol (Camb); 2013 Mar; 5(3):597-605. PubMed ID: 23388834
[TBL] [Abstract][Full Text] [Related]
6. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin.
Yoshida Y; Kurokawa T; Nishikawa Y; Orisa M; Kleinman HK; Kotsuji F
Int J Oncol; 2008 Mar; 32(3):673-81. PubMed ID: 18292945
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Pickl M; Ries CH
Oncogene; 2009 Jan; 28(3):461-8. PubMed ID: 18978815
[TBL] [Abstract][Full Text] [Related]
8. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype.
Sodek KL; Ringuette MJ; Brown TJ
Int J Cancer; 2009 May; 124(9):2060-70. PubMed ID: 19132753
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Prezas P; Arlt MJ; Viktorov P; Soosaipillai A; Holzscheiter L; Schmitt M; Talieri M; Diamandis EP; Krüger A; Magdolen V
Biol Chem; 2006 Jun; 387(6):807-11. PubMed ID: 16800744
[TBL] [Abstract][Full Text] [Related]
10. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
Dong Y; Tan OL; Loessner D; Stephens C; Walpole C; Boyle GM; Parsons PG; Clements JA
Cancer Res; 2010 Apr; 70(7):2624-33. PubMed ID: 20332224
[TBL] [Abstract][Full Text] [Related]
11. Pectasol-C Modified Citrus Pectin targets Galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids.
Hossein G; Halvaei S; Heidarian Y; Dehghani-Ghobadi Z; Hassani M; Hosseini H; Naderi N; Sheikh Hassani S
Cancer Med; 2019 Aug; 8(9):4315-4329. PubMed ID: 31197964
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
13. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.
Shahinian H; Loessner D; Biniossek ML; Kizhakkedathu JN; Clements JA; Magdolen V; Schilling O
Mol Oncol; 2014 Feb; 8(1):68-82. PubMed ID: 24120346
[TBL] [Abstract][Full Text] [Related]
14. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
Ogishima J; Taguchi A; Kawata A; Kawana K; Yoshida M; Yoshimatsu Y; Sato M; Nakamura H; Kawata Y; Nishijima A; Fujimoto A; Tomio K; Adachi K; Nagamatsu T; Oda K; Kiyono T; Osuga Y; Fujii T
BMC Cancer; 2018 Dec; 18(1):1201. PubMed ID: 30509235
[TBL] [Abstract][Full Text] [Related]
15. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients.
Obiezu CV; Scorilas A; Katsaros D; Massobrio M; Yousef GM; Fracchioli S; Rigault de la Longrais IA; Arisio R; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2380-6. PubMed ID: 11489816
[TBL] [Abstract][Full Text] [Related]
16. p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation.
Ip CK; Yung S; Chan TM; Tsao SW; Wong AS
Oncotarget; 2014 Oct; 5(19):9133-49. PubMed ID: 25193855
[TBL] [Abstract][Full Text] [Related]
17. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
[TBL] [Abstract][Full Text] [Related]
19. The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
Chen MW; Yang ST; Chien MH; Hua KT; Wu CJ; Hsiao SM; Lin H; Hsiao M; Su JL; Wei LH
Cancer Res; 2017 Apr; 77(8):1955-1967. PubMed ID: 28209618
[TBL] [Abstract][Full Text] [Related]
20. Ca
Ohya S; Kajikuri J; Endo K; Kito H; Elboray EE; Suzuki T
Cancer Sci; 2021 Sep; 112(9):3769-3783. PubMed ID: 34181803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
